Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
293.42B
Market cap293.42B
Price-Earnings ratio
33.66
Price-Earnings ratio33.66
Dividend yield
2.78%
Dividend yield2.78%
Average volume
11.28M
Average volume11.28M
High today
$120.04
High today$120.04
Low today
$117.87
Low today$117.87
Open price
$119.78
Open price$119.78
Volume
1.75M
Volume1.75M
52 Week high
$125.14
52 Week high$125.14
52 Week low
$76.66
52 Week low$76.66

Stock Snapshot

With a market cap of 293.42B, Merck(MRK) trades at $118.80. The stock has a price-to-earnings ratio of 33.66 and currently yields dividends of 2.8%.

As of 2026-06-10, Merck(MRK) stock has fluctuated between $117.87 and $120.04. The current price stands at $118.80, placing the stock +0.8% above today's low and -1.0% off the high.

The Merck(MRK)'s current trading volume is 1.75M, compared to an average daily volume of 11.28M.

In the last year, Merck(MRK) shares hit a 52-week high of $125.14 and a 52-week low of $76.66.

In the last year, Merck(MRK) shares hit a 52-week high of $125.14 and a 52-week low of $76.66.

MRK News

Benzinga 21h
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial

While the combo showed a numerical improvement in progression-free survival, it did not reach statistical significance, and investigators said the probability o...

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial
TipRanks 2d
Merck, Gilead announce discontinuation of Phase 3 KEYNOTE-D46/EVOKE-03 study

Merck (MRK) and Gilead Sciences (GILD) announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead’s Trodelvy in combination wi...

24/7 Wall St. 3d
Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech By Thomas Richmond Published Jun 7, 9:30AM EDT Quick Read Merck's Keytr...

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

Analyst ratings

70%

of 30 ratings
Buy
70%
Hold
30%
Sell
0%

More MRK News

Simply Wall St 6d
Calderasib–Keytruda Breakthrough Therapy Status Might Change The Case For Investing In Merck

In late May 2026, Merck reported that its investigational KRAS G12C inhibitor calderasib (MK-1084), when combined with KEYTRUDA, received FDA Breakthrough Thera...

Calderasib–Keytruda Breakthrough Therapy Status Might Change The Case For Investing In Merck
Nasdaq 6d
Merck: Navigating the Patent Cliff and Future Growth Prospects

Explore the exciting world of Merck (NYSE: MRK) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain...

Merck: Navigating the Patent Cliff and Future Growth Prospects
TipRanks 6d
Merck settles most Gardasil suits for over $50M, Bloomberg says

Merck (MRK) told Bloomberg in an emailed statement that it will pay more than $50M to settle over 200 lawsuits relating to its Gardasil HPV vaccine. The deal re...

Simply Wall St 7d
Lawsuit Puts Merck Animal Health Disclosures And Valuation Gap In Focus

A securities fraud class action lawsuit has been filed against Merck (NYSE:MRK) over alleged misleading statements about product performance and competition in...

Lawsuit Puts Merck Animal Health Disclosures And Valuation Gap In Focus

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.